Our scientists created a proprietary technology called Radio-Frequency (RF) Spectroscopy to identify cancerous tissue in real time, enabling immediate reaction by the physician during the procedure.

Our technology utilizes RF electrical fields, similar to the frequency range of FM radio, to identify microscopic residual cancerous lesions at the area of tissue being examined.

The technology is based on two main principles:

  1. Reflection of electromagnetic fields depends on the underlying electrical properties of the tissue they interact with
  2. Electrical properties of cancerous tissue are different from those of normal tissue

It is also important to understand that tissue is complex, with various components of the tissue contributing to its electrical properties. Any change in a cell’s physiological state will be reflected in its electrical response. (see photo below) Our technology can capture these changes and provide immediate feedback to physicians if tissue is malignant or benign.

Reasons for Bioelectric Differences



Alterations in nuclear content and size

Membrane depolarization

Increased vascularity, changes in spatial cellular connectivity, mobility of conductive ions within the tissue

Tumor stroma reaction altering tissue structure in vicinity of malignancy

Smart Biopsy Device

Dilon Devices has expanded upon the real-time, tissue characterization capability of our radio-frequency (RF) spectroscopy technology with the development of the Smart Biopsy Device, a percutaneous soft tissue biopsy device. Miniaturizing the sensors, a key component of the project, represents an important step forward in the future development of Dilon’s multi-cancer applications. Dilon has completed the first phase of development for this device through the European Union Horizon 2020 research and innovation program, a program developed to help entrepreneurs take great ideas from lab to market while removing barriers to innovation.

The Smart Biopsy Device has entered into feasibility testing, which includes ex-vivo verification within mastectomy tissue. The first study site, Meir Medical Center in Kfar Saba, Israel has used the device in twelve ex-vivo cases to date, with two additional locations in Israel and sites in Europe to follow in the near future. The outcome of these trials is expected to verify the accuracy of the Smart Biopsy Device technology in the real-time identification of the tissue type that is sampled and extracted with the needle.

“The development of this Smart Biopsy Device substantiates the application of radio-frequency spectroscopy and establishes Dune as a leader in tissue characterization for cancer,” said Lori Chmura, Dilon CEO.

You can click here to view the full press release on our Smart Biopsy Device.

Contact Us